Welcome to our dedicated page for ProPhase Labs news (Ticker: PRPH), a resource for investors and traders seeking the latest updates and insights on ProPhase Labs stock.
ProPhase Labs, Inc. (PRPH) is a diversified natural health medical science company that specializes in providing a wide range of diagnostic and consumer products. The company's operations are divided into two primary segments: Diagnostic Services and Consumer Products.
The Diagnostic Services segment offers COVID-19 diagnostic testing to a broad range of customers across the United States, including health plans, third-party payers, and government organizations. This segment is focused on delivering timely and accurate diagnostic information, critical during the ongoing pandemic and beyond.
The Consumer Products segment is engaged in the research, development, manufacture, distribution, marketing, and sale of over-the-counter (OTC) healthcare products and dietary supplements within the United States. In addition to these offerings, ProPhase Labs also provides personal genomics products and services, enabling consumers to gain insights into their genetic makeup.
ProPhase Labs is committed to advancing health and wellness through innovative products and services. Recent achievements include the development of the BE-Smart Esophageal Cancer Test, leveraging the company's AI platform and extensive genomics database. This test represents a significant step forward in cancer diagnostics and showcases the company's commitment to leveraging advanced technologies for improved healthcare outcomes.
Moreover, ProPhase Labs has projects such as Project ZenQ-AI and Equivir, which underline the company's focus on continuous research and innovation. These initiatives highlight ProPhase Labs' role in pushing the boundaries of medical science and consumer health products.
Financially, ProPhase Labs maintains a solid position, with ongoing projects and partnerships further strengthening its market presence. The company actively communicates with its retail investors through multiple channels, ensuring transparency and engagement with its stakeholders.
For more information, visit ProPhase Labs.
ProPhase Labs (Nasdaq: PRPH) has acquired Nebula Genomics for approximately $14.6 million, using a combination of cash and stock. This acquisition aims to merge Nebula's whole genome sequencing services with ProPhase's diagnostic testing, enhancing their offerings in personalized medicine. George Church, the founder of Nebula, will lead ProPhase's new Scientific Advisory Board. The move is expected to make genome sequencing more accessible and cost-effective, while leveraging ProPhase's existing retail network to expand its reach.
ProPhase Labs, Inc. (NASDAQ: PRPH) will hold a conference call on August 13, 2021 at 11:00 a.m. ET to discuss its Q2 2021 results. CEO Ted Karkus will lead the call, which includes a question-and-answer session. Participants can register online and will receive dial-in details upon registration. Those without internet access can join via toll-free and international phone numbers. The call will be streamed live and available for replay shortly after.
ProPhase Labs provides a range of clinical diagnostics and testing services, including COVID-19 testing with results in under 24 hours.
ProPhase Labs (Nasdaq: PRPH) announced that CEO Ted Karkus will present a corporate overview during the Access to Giving Virtual Investor Conference from July 13-15, 2021. Karkus's presentation is scheduled for July 15 at 9:30 AM ET, with management available for one-on-one meetings throughout the event. ProPhase Labs specializes in medical science and technology, including diagnostic testing for COVID-19 and other respiratory illnesses, with results provided in under 24 hours. For more details, visit www.ProPhaseLabs.com.
ProPhase Labs (Nasdaq: PRPH) has engaged CORE IR for investor relations and public relations support to enhance market awareness and communicate its business model effectively. CORE IR aims to expand ProPhase's institutional and retail investor base through its strategic advisory services. CEO Ted Karkus emphasized the company's unique growth story and diversification strategy. The partnership is expected to facilitate greater outreach and engagement with investors, aligning with ProPhase's objectives in the medical science and technology sector.
ProPhase Labs, Inc. (Nasdaq: PRPH) has been added to the Russell Microcap Index as of June 28, 2021, following the annual reconstitution of Russell Indexes. This inclusion is expected to enhance company awareness among a broader investor base and improve liquidity. FTSE Russell determines membership through market-capitalization rankings. The Russell Indexes are widely recognized benchmarks for investment managers, with approximately $10.6 trillion in assets linked to them. ProPhase Labs offers clinical diagnostic services, including COVID-19 testing, under its subsidiary ProPhase Diagnostics.
ProPhase Labs (NASDAQ: PRPH) has formed two subsidiaries: ProPhase Precision Medicine focusing on genomics testing, and ProPhase Global Healthcare for international COVID-19 testing. ProPhase Precision Medicine aims to acquire technologies for whole-genome sequencing (WGS), crucial for understanding genetic disorders and drug responses. The drop in WGS costs opens up a multi-billion-dollar genomic diagnostics market. The company also seeks to expand COVID-19 testing internationally, leveraging increased global demand.
ProPhase Labs (NASDAQ: PRPH) announced that CEO Ted Karkus will present at the LD Micro Invitational XI virtual conference on June 10, 2021, at 1:00 p.m. EDT. The conference runs from June 8-10, 2021, and Karkus will discuss the company's diverse medical science and technology initiatives. ProPhase Labs focuses on clinical diagnostics and testing services, particularly in COVID-19 and influenza testing, providing results in under 24 hours. For more details, visit ProPhaseLabs.com.
ProPhase Labs reported a remarkable 709% revenue increase in Q1 2021, totaling $15.3 million, driven primarily by its new diagnostic services. Gross profit surged to $8.9 million, yielding a net income of $1.1 million or $0.07 per share. The company declared a special cash dividend of $0.30 per share, payable on June 3, 2021. Recent contracts will provide reliable COVID-19 testing to nearly 600,000 residents in New York. The company boasts $36.3 million in cash and equivalents as of March 31, 2021, signaling a strong financial position.
ProPhase Labs (Nasdaq: PRPH) has secured a contract with Dutchess County, NY, to provide COVID-19 testing for nearly 300,000 residents. The company’s 99% accurate multiplex RT-PCR testing will deliver results within 24 hours directly to patients’ smartphones. This initiative enhances local reopening efforts, coinciding with the start of the Hudson Valley Renegades' baseball season. Testing will commence on May 9, 2021, at Dutchess Stadium, with no out-of-pocket costs for residents.
ProPhase Labs has signed a contract with The Town of Oyster Bay, NY, to provide COVID-19 testing for its residents. This partnership aims to facilitate a safe reopening for the community, offering reliable and fast saliva-based viral RT-PCR testing. Test results will be available within 24 hours, targeting schools and major community events initially. The initiative is part of broader efforts to help local residents return to normal activities.
FAQ
What is the current stock price of ProPhase Labs (PRPH)?
What is the market cap of ProPhase Labs (PRPH)?
What does ProPhase Labs, Inc. do?
What are the main segments of ProPhase Labs' operations?
What services does the Diagnostic Services segment provide?
What products are offered in the Consumer Products segment?
What is the BE-Smart Esophageal Cancer Test?
What recent projects has ProPhase Labs undertaken?
How does ProPhase Labs engage with its investors?
How does ProPhase Labs contribute to healthcare?
